NCT00977171View on ClinicalTrials.gov

Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Chronic Fatigue SyndromeOrthostatic HypotensionNeurally Mediated HypotensionNeurogenic Orthostatic Hypotension
Interventions
DRUG

Droxidopa

Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period

Trial Locations (1)

28226

7421 Carmel Executive Park Drive, Ste. 320, Charlotte

Sponsors
All Listed Sponsors
lead

Chelsea Therapeutics

INDUSTRY